Absence of a difference in the neurosecretory activity of supraoptic nucleus vasopressin neurons of neuroleptic-treated schizophrenic patients

Neuroendocrinology

Volumn 82, Issue 2, 2005, Pages 63-69

  Malidelis, Yiannis I ^a,b   Panayotacopoulou, Maria T ^a,b   Van Heerikhuize, Joop J ^c   Unmehopa, Unga A ^c   Kontostavlaki, Dimitra P ^a,b   Swaab, Dick F ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY MENTAL HEALTH RESEARCH INSTITUTE   (Greece)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Clinical neuroendocrinology; Neuroleptics; Schizophrenia; Supraoptic nucleus; Tyrosine hydroxylase; Vasopressin

Indexed keywords

FORMALDEHYDE; NEUROLEPTIC AGENT; PARAFFIN; TYROSINE 3 MONOOXYGENASE; VASOPRESSIN;

ADULT; AGED; ARTICLE; AUTOPSY; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST; FEMALE; GENE EXPRESSION; GOLGI COMPLEX; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; IN SITU HYBRIDIZATION; MALE; MORPHOMETRICS; NEUROSECRETION; PRIORITY JOURNAL; RANK SUM TEST; SCHIZOPHRENIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUPRAOPTIC NUCLEUS;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; GOLGI APPARATUS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEURONS; ORGAN SIZE; RNA, MESSENGER; SCHIZOPHRENIA; SUPRAOPTIC NUCLEUS; TYROSINE 3-MONOOXYGENASE; VASOPRESSINS;

EID: 33644536715     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090981     Document Type: Article

References (60)

1. Raskind MA, Orenstein H, Christopher TG: Acute psychosis, increased water ingestion, and inappropriate antidiuretic hormone secretion. Am J Psychiatry 1975;132:907-910.
2. Raskind MA, Courtney N, Murburg MM, Backus FI, Bokan JA, Ries RK, Dorsa DM, Weitzman RE: Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry 1987;22:453-462.
3. Goldman MB, Luchins DJ, Robertson GL: Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med 1988;318:397-403.
4. Goldman MB, Robertson GL, Luchins DJ, Hedeker D, Pandey GN: Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 1997;54:443-449.
5. Emsley R, Potgieter A, Taljaard F, Joubert G, Gledhill R: Water excretion and plasma vasopressin in psychotic disorders. Am J Psychiatry 1989;146:250-253.
6. Sarai M, Matsunaga H: ADH secretion in schizophrenic patients on antipsychotic drugs. Biol Psychiatry 1989;26:576-580.
7. Riggs AT, Dysken MW, Kim SW, Opsahl JA: A review of disorders of water homeostasis in psychiatric patients. Psychosomatics 1991;32:133-148.
8. Ohsawa H, Kishimoto T, Shimayoshi N, Matsumura K, Tahara K, Kitera K, Higashiura N, Noriyama Y, Matsumoto H, Hirai M: Atrial natriuretic peptide and arginine vasopressin secretion in schizophrenic patients. Acta Psychiatr Scand 1993;88:130-134.
9. de Leon J, Verghese C, Tracy JI, Josiassen RC, Simpson GM: Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biol Psychiatry 1994;35:408-419.
10. Spigset O, Hendenmalm K: Hyponatremia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf 1995;12:209-225.
11. de Leon J: Polydipsia: a study in a long-term psychiatric unit. Eur Arch Psychiatry Clin Neurosci 2003;253:37-39.
12. Fricchione G, Kelleher S, Ayyala M: Coexisting central diabetes insipidus and psychogenic polydipsia. J Clin Psychiatry 1987;48:75-76.
13. Costanzo ES, Antes LM. Christensen AJ: Behavioral and medical treatment of chronic polydipsia in a patient with schizophrenia and diabetes insipidus. Psychosom Med 2004;66:283-286.
14. Ishunina TA, Swaab DF: Vasopressin and oxytocin neurons of the human supraoptic and paraventricular nucleus: size changes in relation to sex and age. J Clin Endocrinol Metab 1999;84:4637-4644.
15. Ishunina TA, Salehi A, Hofman MA, Swaab DF: Activity of vasopressinergic neurons of the human supraoptic nucleus is age and sex dependent. J Neuroendocrinol 1999;11:251-258.
16. Lucassen PJ, Goudsmit E, Pool CW, Mengod G, Palacios JM, Raadskeer FC, Guldenaar SE, Swaab DF: In situ hybridization for vasopressin mRNA in the human supraoptic and paraventricular nucleus. J Neurosci Methods 1995;57:221-230.
17. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1471-1486.
18. Farrison PJ: Dopamine and schizophrenia - proof at last? Lancet 2000;356:958-959.
19. Panayotacopoulou MT, Malidelis YI, Fliers E, Bouras C, Ravid R, Swaab DF: Increased expression of tyrosine hydroxylase immunoreactivity in paraventricular and supraoptic neurons in illnesses with prolonged osmotic or nonosmotic stimulation of vasopressin release. Neuroendocrinology 2002;76:254-266.
20. Swaab DF: The human hypothalamus: basic and clinical aspects. I. Nuclei of the hypothalamus. In Aminoff MJ, Boller F, Swaab DF (eds): Handbook of Clinical Neurology, 3rd Ser. Amsterdam, Elsevier, 2003.
21. Swaab DF, Hofman MA, Honnebier MB: Development of vasopressin neurons in the human suprachiasmatic nucleus in relation to birth. Brain Res Dev Brain Res 1990;52:289-293.
22. Panayotacopoulou MP, Swaab DF: Development of tyrosine hydroxylase-immunoreactive neurons in the human paraventricular and supraoptic nucleus. Brain Res Dev Brain Res 1993;72:145-150.
23. Hou-Yu A, Lamme AT, Zimmerman EA, Silverman AJ: Comparative distribution of vasopressin and oxytocin neurons in the rat brain using a double label procedure. Neuroendocrinology 1986;44:235-246.
24. Panayotacopoulou MT, Raadsheer FC, Swaab DF: Colocalization of tyrosine hydroxylase with oxytocin and vasopressin in neurons of the human paraventricular and supraoptic nucleus. Brain Res Dev Brain Res 1994;83:59-66.
25. Panayotacopoulou MT, Goudsmit E, Van Heerikhuize JJ, Swaab DF: Simultaneous detection of tyrosine hydroxylase immunoreactivity and vasopressin mRNA in neurons of the human paraventricular and supraoptic nucleus. Brain Res 2000;855:181-185.
26. Lucassen PJ, Ravid R, Gonatas NK, Swaab DF: Activation of the human supraoptic and paraventricular nucleus neurons with aging in Alzheimer's disease as judged from increasing size of the Golgi apparatus. Brain Res 1993;632:105-113.
27. Salehi A, Lucassen PJ, Pool CW, Gonatas NK, Ravid R, Swaab DF: Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer's disease as suggested by the size of the Golgi apparatus. Neuroscience 1994;59:871-880.
28. Shi SR, Key ME, Kalra KM: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
29. Gonatas JO, Mezitis SG, Stierber A, Fleischer B, Gonatas NK: MG-160, a novel sialoglycoprotein of the medial cisternae of the Golgi apparatus. J Biol Chem 1989;264:646-653.
30. Croul S, Mezitis SG, Stierber A, Chen Y, Gonatas JO, Goud B, Gonatas NK: Immunohistochemical visualization of the Golgi apparatus in several species, including human, and tissues with an antiserum against MG-160, a sialoglycoprotein of rat Golgi apparatus. J Histochem Cytochem 1990;38:957-963.
31. Panayotacopoulou MT, Guntern R, Bouras C, Issidorides MR, Constantinidis J: Tyrosine hydroxylase immunoreactive neurons in the paraventricular and supraoptic nuclei of the human brain demonstrated by a method adapted to prolonged formalin fixation. J Neurosci Methods 1991;39:39-44.
32. Verwer RW, Raber-Durlacher JE: Efficient and unbiased estimation of volume and area of tissue components and cell number in gingival biopsies. J Periodontal Res 1993;28:313-323.
33. Mengod G, Goudsmit E, Probst A, Palacios JM: In situ hybridization histochemistry in the human hypothalamus. Prog Brain Res 1992;93:45-55.
34. Szot P, Leverenz JB, Peskind ER, Kiyasu E, Rohde K, Miller MA, Raskind MA: Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the locus coeruleus in Alzheimer's disease. Brain Res Mol Brain Res 2000;84:135-140.
35. Goldman MB, Robertson GL, Luchins DJ, Hedecker D: The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients. J Clin Endocrinol Metab 1996;81:1465-1470.
36. Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S: Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 1991;83:273-277.
37. Lesch A, Bogerts B: The diencephalon in schizophrenia: evidence for reduced thickness of the periventricular grey matter. Eur Arch Psychiatry Neurol Sci 1984;234:212-219.
38. Fannon D, Chitnis X, Doku V, Tennakoon L, O'Ceallaigh S, Soni W, Sumich A, Lowe J, Santamaria M, Sharma T: Features of structural brain abnormality detected in first-episode psychosis. Am J Psychiatry 2000;157:1829-1834.
39. Cahn W, Hulsoff Pol HE, Bongers M, Schnack HG, Mandl RC, van Haren NE, Durston S, Koning H, van der Linden JA, Kahn RS: Brain morphology in antipsychotic-naïve schizophrenia: a study of multiple brain structures. Br J Psychiatry 2002;181(Suppl 43):S66-S72.
40. Stevens JR: Neuropathology of schizophrenia. Arch Gen Psychiatry 1982;39:1131-1139.
41. Mai JK, Berger K, Sofroniew MV: Morphometric evaluation of neurophysin immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 1993;34:133-154.
42. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B: Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998;83:867-875.
43. Bernstein HG, Jirikowski GF, Heinemann A, Baumann B, Hornstein C, Danos P, Dieckmann S, Sauer H, Keilhoff G, Bogerts B: Low and infrequent expression of nitric oxide synthase/NADPH-diaphorase in neurons of the human supraoptic nucleus: a histochemical study. J Chem Neuroanat 2000;20:177-183.
44. Bernstein HG, Heinemann A, Krell D, Dobrowolny H, Bielau H, Keilhoff G, Bogerts B: Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus. Cell Mol Biol (Noisy-le-Grand) 2005;51:279-284.
45. Ichinose H, Ohye T, Fujita K, Pantucek F, Lange K, Riederer P, Nagatsu T: Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm 1994;8:149-158.
46. Schrier RW, Bichet DG: Osmotic and nonosmotic control of vasopressin release and the pathogenesis of impaired water excretion in adrenal, thyroid and edematous disorders. J Lab Clin Med 1981;98:1-15.
47. Schrier RW: Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990;113:155-159.
48. Kovacs L, Robertson GL: Syndrome of inappropriate antidiuresis. Endocrinol Metab Clin North Am 1992;21:859-875.
49. Kitahama K, Ikemoto K, Jouvet A, Nagatsu I, Sakamoto N, Pearson J: Aromatic L-amino acid decarboxylase and tyrosine hydroxylase immunohistochemistry in the adult human hypothalamus. J Chem Neuroanat 1998;16:43-55.
50. Holzbauer M, Muscholl E, Racke K, Sharman DF: Evidence that dopamine is a neurotransmitter in the neurointermediate lobe of the hypophysis. Prog Brain Res 1983;60:357-364.
51. Pittman QJ, Lawrence D, Lederis K: Presynaptic interactions in the neurohypophysis: endogenous modulators of release. Prog Brain Res 1983;60:319-332.
52. Forsling ML, Williams H: Central effects of dopamine on vasopressin release in the normally hydrated and water-loaded rat. J Physiol 1984;346:49-59.
53. Lightman SL, Forsling M: Evidence for dopamine as an inhibitor of vasopressin release in man. Clin Endocrinol (Oxf) 1980;12:39-45.
54. Legros JJ, Gazzotti C, Carvelli T, Franchimont P, Timsit-Berthier M, von Frenckell R, Ansseau M: Apomorhine stimulation of vasopressin- and oxytocin-neurophysins: evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology 1992;17:611-617.
55. Lieberman JA, Kane JM, Alvir J: Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415-433.
56. Sharma RP, Javaid JI, Pandey GN, Janicak PG. Davis JM: Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol Psychiatry 1991;30:459-466.
57. Leadbetter RA, Shutty MS Jr, Elkashef AM, Kirch DG, Spraggins T, Cail WS, Wu H, Bilder RM, Lieberman JA, Wyatt RJ: MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. Am J Psychiatry 1999;156:958-960.
58. Emsley R, Roberts M, Smith R, Spangenberg J, Chalton DO: Disordered water homeostasis in schizophrenia and cerebral ventricular size. Br J Psychiatry 1995;166:501-506.
59. Emsley RA, Spangenberg JJ, Roberts MC, Taljaard FJ, Chalton DO: Disordered water homeostasis and cognitive impairment in schizophrenia. Biol Psychiatry 1993;34:630-633.
60. Umbricht D: Polydipsia and hippocampal pathology. Biol Psychiatry 1994;36:708-710.